Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration. Backed by specialist life science investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with significant clinical and commercial differentiation. Skye plans to launch a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist. SBI-100 Ophthalmic Emulsion, a CB1 agonist, is being studied in a Phase 2 trial of patients with glaucoma and ocular hypertension. Skye expects top-line data from its Phase 2a glaucoma study this quarter.
Skye Bioscience, Inc.
11250 El Camino Real
Suite 100
San Diego, CA 92130
SKYE Investor Relations
T: (858) 410-0266
ir@skyebioscience.com
ClearTrust, LLC
16540 Pointe Village Dr.
Suite 210
Lutz, FL 33558
T: 813-235-4490
www.ClearTrustOnline.com
Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.